Background and Objective: Direct (new) Oral Anticoagulants (DOACs) have emerged as a
contemporary and promising option in the treatment of thromboses and VTE, while …

Abstract Study Objective Direct oral anticoagulants are the standard of care for venous
thromboembolism (VTE) treatment. These agents are recommended regardless of patient …

Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Background Emerging safety and efficacy data for rivaroxaban suggest traditional therapy
and rivaroxaban are comparable in the morbidly obese. However, real‐world data that …

Abstract Background Direct oral anticoagulants (DOACs) are recommended in preference to
traditional anticoagulants (LMWH±warfarin) for treating acute venous thromboembolism …

One of the most important advantages of direct oral anticoagulants (DOACs) over warfarin is
that DOACs can be given in fixed doses without routine coagulation monitoring, which …

Novel oral anticoagulants (NOACs) are the recent therapeutic breakthrough in the
thromboprophylaxis of non-valvular atrial fibrillation (NVAF). There are currently three …

Objective. To evaluate the effect of body weight (BW) on safety and efficacy of direct oral
anticoagulants (DOACs). Methods. We performed a meta-analysis of randomized controlled …

Introduction As a result of limited clinical data, guidelines do not recommend the use of non-
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …

Background Rivaroxaban is a first-line option for the management of venous
thromboembolism (VTE). However, limited data are available regarding its effectiveness in …